Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 687-690

  Ferrer, Elena ^a   Podzamczer, Daniel ^a   Arnedo, Mireia ^b   Fumero, Emilio ^a   McKenna, Paula ^c   Rinehart, Alex ^d   Pérez, José L ^a   Barberá, María J ^a   Pumarola, Tomás ^b   Gatell, José M ^b   Gudiol, Francisco ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Virco BVBA   (Belgium)

^d Tibotec Virco USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGENTINA; COHORT STUDIES; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MIDDLE AGED; MUTATION; NELFINAVIR; NEVIRAPINE; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN; TREATMENT FAILURE; ZIDOVUDINE;

EID: 0037443127     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/367987     Document Type: Article

References (15)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:113-6.
3. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
4. Podzamczer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Expert Opin Pharmacother 2001; 2:2065-78.
5. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to ZDV/3TC in HIV-infected naive patients (The Combine Study). Antiviral Therapy 2002; 7:81-90.
6. Workman C, Hales G, Mc Kenna P, for the CREST Study Group. CREST: a randomised comparison of two resistance test platforms: genotype and virtual phenotype [abstract 587-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:270.
7. Soriano V. Sequencing antiretroviral drugs. AIDS 2001; 15:547-51.
8. Staszewswki S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-73.
9. Havlir DV, Helmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-34.
10. Puig T, Perez-Olmeda M, Rubio A, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. ERASE-2 Study Group. AIDS 2000; 14:727-32.
11. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 2001; 15:1894-6.
12. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-9.
13. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-18.
14. Mazzota F, Lo Caputo S, Torti C, et al. Real vs. virtual phenotype: 12-month results from the GenPherex Study [abstract 589-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:270.
15. Pérez-Elías M, García-Arata I, Muñoz V, et al. A randomized, prospective study of phenotype versus virtual phenotype testing for patients failing antiretroviral therapy [abstract 586-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:269.